Improved control over MSCs behavior within 3D matrices by using different cell loads in both in vitro and in vivo...

Area of Science:

• Biomaterials Science
• Cell Therapy
• Regenerative Medicine

Background:

• Multipotent mesenchymal stromal cells (MSCs) are crucial for cell-based therapies.
• Cell microencapsulation in biomaterials enhances drug delivery systems.
• Erythropoietin (EPO)-secreting MSCs are utilized for therapeutic protein delivery.

Purpose of the Study:

• To investigate the impact of initial cell density on EPO-secreting MSC behavior within alginate microcapsules.
• To evaluate the efficacy of these microencapsulated systems as drug delivery platforms in vitro and in vivo.
• To determine optimal cell seeding densities for successful cell-based therapies.

Main Methods:

• Immobilization of EPO-secreting MSCs in alginate microcapsules at various densities.
• In vitro assessment of cell proliferation and EPO secretion over time.
• In vivo implantation studies to evaluate capsule performance and longevity.
• Analysis of microenvironmental factors like space saturation and oxygen levels within capsules.

Main Results:

• In vitro: Higher cell densities resulted in sustained EPO secretion; lower densities showed increasing cell numbers and EPO levels.
• In vivo: High cell densities led to rapid space saturation, oxygen depletion, and implant failure.
• In vivo: Lower cell densities demonstrated prolonged EPO release with a steady increase in secretion.

Conclusions:

• Initial cell density significantly influences the performance of microencapsulated cell-based drug delivery systems.
• In vivo oxygen depletion and space saturation at high cell densities compromise therapeutic outcomes.
• Tailoring cell load to the microenvironment is essential for optimizing cell-based therapy efficacy and longevity.